image
Healthcare - Biotechnology - NASDAQ - IE
$ 16.73
0.48 %
$ 6.92 B
Market Cap
-3.8
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one AMRN stock under the worst case scenario is HIDDEN Compared to the current market price of 16.7 USD, Amarin Corporation plc is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one AMRN stock under the base case scenario is HIDDEN Compared to the current market price of 16.7 USD, Amarin Corporation plc is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one AMRN stock under the best case scenario is HIDDEN Compared to the current market price of 16.7 USD, Amarin Corporation plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AMRN

image
$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
229 M REVENUE
-25.51%
-91.8 M OPERATING INCOME
-35.82%
-82.2 M NET INCOME
-39.03%
-31 M OPERATING CASH FLOW
-450.87%
-46 M INVESTING CASH FLOW
-80.14%
-1.44 M FINANCING CASH FLOW
-627.39%
42 M REVENUE
-32.56%
-16.8 M OPERATING INCOME
68.10%
-15.7 M NET INCOME
67.41%
-12.5 M OPERATING CASH FLOW
6.39%
12.1 M INVESTING CASH FLOW
153.02%
-1.12 M FINANCING CASH FLOW
-6582.35%
Balance Sheet Amarin Corporation plc
image
Current Assets 595 M
Cash & Short-Term Investments 294 M
Receivables 122 M
Other Current Assets 179 M
Non-Current Assets 90 M
Long-Term Investments 0
PP&E 7.61 M
Other Non-Current Assets 82.3 M
42.93 %17.84 %26.10 %12.01 %Total Assets$685.3m
Current Liabilities 180 M
Accounts Payable 40.4 M
Short-Term Debt 0
Other Current Liabilities 140 M
Non-Current Liabilities 19.2 M
Long-Term Debt 7.72 M
Other Non-Current Liabilities 11.5 M
20.27 %70.08 %3.88 %5.77 %Total Liabilities$199.2m
EFFICIENCY
Earnings Waterfall Amarin Corporation plc
image
Revenue 229 M
Cost Of Revenue 150 M
Gross Profit 81.4 M
Operating Expenses 173 M
Operating Income -91.8 M
Other Expenses -9.61 M
Net Income -82.2 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)229m(150m)81m(173m)(92m)10m(82m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
35.60% GROSS MARGIN
35.60%
-40.15% OPERATING MARGIN
-40.15%
-35.95% NET MARGIN
-35.95%
-16.90% ROE
-16.90%
-11.99% ROA
-11.99%
-19.34% ROIC
-19.34%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amarin Corporation plc
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -82.2 M
Depreciation & Amortization 3.01 M
Capital Expenditures 0
Stock-Based Compensation 17.7 M
Change in Working Capital 36.2 M
Others -9.23 M
Free Cash Flow -31 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amarin Corporation plc
image
Wall Street analysts predict an average 1-year price target for AMRN of $2.17 , with forecasts ranging from a low of $1.5 to a high of $3 .
AMRN Lowest Price Target Wall Street Target
1.5 USD -91.03%
AMRN Average Price Target Wall Street Target
2.17 USD -87.05%
AMRN Highest Price Target Wall Street Target
3 USD -82.07%
Price
Max Price Target
Min Price Target
Average Price Target
181816161414121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Amarin Corporation plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
102 K USD 1
9-12 MONTHS
7. News
Are Medical Stocks Lagging Amarin (AMRN) This Year? Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year. zacks.com - 2 weeks ago
Best Momentum Stock to Buy for June 27th GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025. zacks.com - 3 weeks ago
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs. zacks.com - 3 weeks ago
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. zacks.com - 3 weeks ago
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA ® IN EUROPE globenewswire.com - 3 weeks ago
Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy? From a technical perspective, Amarin Corporation PLC (AMRN) is looking like an interesting pick, as it just reached a key level of support. AMRN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world. zacks.com - 1 month ago
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? Here is how Amarin (AMRN) and GSK (GSK) have performed compared to their sector so far this year. zacks.com - 1 month ago
Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock? Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 month ago
Best Momentum Stocks to Buy for June 10th AMRN, FIX and PATH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2025. zacks.com - 1 month ago
New Strong Buy Stocks for June 10th FIX, GHLD, AMRN, VCISY and NWFL have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2025. zacks.com - 1 month ago
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis. zacks.com - 2 months ago
Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript Amarin Corporation plc (NASDAQ:AMRN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Operator Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin. seekingalpha.com - 2 months ago
8. Profile Summary

Amarin Corporation plc AMRN

image
COUNTRY IE
INDUSTRY Biotechnology
MARKET CAP $ 6.92 B
Dividend Yield 0.00%
Description Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Contact Grand Canal Docklands, Dublin, 2 https://www.amarincorp.com
IPO Date April 1, 1993
Employees 275
Officers Dr. Nabil Abadir Chief Medical Officer of Global Medical Affairs Dr. Steven B. Ketchum Ph.D. Executive Vice President, President of Research & Development and Chief Scientific Officer Mr. Jonathan N. Provoost Executive Vice President, Chief Legal & Compliance Officer and Secretary Mr. Laurent Abuaf President of Europe & Senior Vice President Mr. Jordan Zwick Senior Vice President of Corporate Business Development & Investor Relations Mr. Aaron D. Berg Chief Executive Officer, President & Director Mr. Peter L. Fishman Chief Financial Officer Dr. David Keenan Ph.D. Executive Vice President of Technical Operations & President of Europe